A Product and Pipeline Analysis of the Human Plasma-derived Therapeutics Market
The global human plasma-derived therapeutics market, worth $billion in 2015, is set to grow at a CAGR of % to reach $ billion by 2021.
Rise in the global ageing population, increased awareness about the potential of plasma-derived therapeutics, early diagnosis of diseases, and the growing popularity of plasma-derived products in the emerging economies are the key factors driving the growth.
However, there are significant challenges in handling the strict regulations of different countries with respect to selection of donors, plasma screening process, and fractionation process.
In 2015, CSL Behring, Baxter, Grifols, Kedrion, and Octapharma were the top competitors; however, companies such as Sanquin are gaining ground quickly.
In the past, there have been significant consolidations such as the $ billion acquisition of Talecris in 2011 by Grifols. The market is further expected to witness big industry consolidations for economies of scale and market access.
The IVIG segment will continue to be the market driver because of the heavy R&D investment in biologics development by market leaders such as Grifols, Octapharma, and CSL Behring.
A recent pre-clinical research study at Stanford University showed that blood plasma derived from young mice and injected into older mice rejuvenated the health and memory of the older mice. Several other studies like this one may open up new indications such as Alzheimer’s disease and other age-related diseases for the human plasma-derived therapeutics market in the coming years.
Electronic Access - Site License Fulfilled By Publisher
Electronic Access - Global site License Fulfilled By Publisher